These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32920022)

  • 1. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease.
    Wolfe R; Wetmore JB; Woods RL; McNeil JJ; Gallagher H; Roderick P; Walker R; Nelson MR; Reid CM; Shah RC; Ernst ME; Lockery JE; Tonkin AM; Abhayaratna WP; Gibbs P; Wood EM; Mahady SE; Williamson JD; Donnan GA; Cloud GC; Murray AM; Polkinghorne KR
    Kidney Int; 2021 Feb; 99(2):466-474. PubMed ID: 32920022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
    McNeil JJ; Wolfe R; Woods RL; Tonkin AM; Donnan GA; Nelson MR; Reid CM; Lockery JE; Kirpach B; Storey E; Shah RC; Williamson JD; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Orchard SG; Trevaks RE; Beilin LJ; Johnston CI; Ryan J; Radziszewska B; Jelinek M; Malik M; Eaton CB; Brauer D; Cloud G; Wood EM; Mahady SE; Satterfield S; Grimm R; Murray AM;
    N Engl J Med; 2018 Oct; 379(16):1509-1518. PubMed ID: 30221597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
    Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
    Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
    Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.
    McNeil JJ; Woods RL; Nelson MR; Murray AM; Reid CM; Kirpach B; Storey E; Shah RC; Wolfe RS; Tonkin AM; Newman AB; Williamson JD; Lockery JE; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Trevaks RE; Orchard SG; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Grimm RH;
    J Gerontol A Biol Sci Med Sci; 2017 Oct; 72(11):1586-1593. PubMed ID: 28329340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.
    ASPREE Investigator Group
    Contemp Clin Trials; 2013 Nov; 36(2):555-64. PubMed ID: 24113028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Aspirin on Disability-free Survival in the Healthy Elderly.
    McNeil JJ; Woods RL; Nelson MR; Reid CM; Kirpach B; Wolfe R; Storey E; Shah RC; Lockery JE; Tonkin AM; Newman AB; Williamson JD; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Orchard SG; Trevaks RE; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Ryan J; Radziszewska B; Grimm R; Murray AM;
    N Engl J Med; 2018 Oct; 379(16):1499-1508. PubMed ID: 30221596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "To take or not to take an aspirin?" The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease.
    Major RW; Burton JO
    Kidney Int; 2021 Feb; 99(2):308-310. PubMed ID: 33509351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial.
    Zoungas S; Zhou Z; Owen AJ; Curtis AJ; Espinoza SE; Ernst ME; Woods RL; Orchard SG; McNeil JJ; Murray AM; Nelson MR; Reid CM; Ryan J; Wolfe R
    Lancet Diabetes Endocrinol; 2024 Feb; 12(2):98-106. PubMed ID: 38142708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.
    McNeil JJ; Nelson MR; Woods RL; Lockery JE; Wolfe R; Reid CM; Kirpach B; Shah RC; Ives DG; Storey E; Ryan J; Tonkin AM; Newman AB; Williamson JD; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Orchard SG; Trevaks RE; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Radziszewska B; Grimm R; Murray AM;
    N Engl J Med; 2018 Oct; 379(16):1519-1528. PubMed ID: 30221595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.
    Gupta K; Mehta H; Kim H; Stebbins A; Wruck LM; Muñoz D; Effron MB; Anderson RD; Pepine CJ; Jain SK; Girotra S; DeWalt DA; Whittle J; Benziger CP; Farrehi P; Zhou L; Knowlton KU; Polonsky TS; Bradley SM; Harrington RA; Rothman RL; Jones WS; Hernandez AF
    Am Heart J; 2023 Oct; 264():31-39. PubMed ID: 37290700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population.
    Lewis JP; Riaz M; Xie S; Polekhina G; Wolfe R; Nelson M; Tonkin AM; Reid CM; Murray AM; McNeil JJ; Shuldiner AR; Lacaze P
    Clin Pharmacol Ther; 2020 Dec; 108(6):1289-1298. PubMed ID: 32562573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between CKD and Major Hemorrhage in Older Persons: Data From the Aspirin in Reducing Events in the Elderly Randomized Trial.
    Mahady SE; Polekhina G; Woods RL; Wolfe R; Wetmore JB; Margolis KL; Wood EM; Cloud GC; Murray AM; Polkinghorne KR
    Kidney Int Rep; 2023 Apr; 8(4):737-745. PubMed ID: 37069989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
    Pallikadavath S; Ashton L; Brunskill NJ; Burton JO; Gray LJ; Major RW
    Eur J Prev Cardiol; 2022 Feb; 28(17):1953-1960. PubMed ID: 34448849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.
    Mann JFE; Joseph P; Gao P; Pais P; Tyrwhitt J; Xavier D; Dans T; Jaramillo PL; Gamra H; Yusuf S;
    Kidney Int; 2023 Feb; 103(2):403-410. PubMed ID: 36341885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.
    Jardine MJ; Ninomiya T; Perkovic V; Cass A; Turnbull F; Gallagher MP; Zoungas S; Lambers Heerspink HJ; Chalmers J; Zanchetti A
    J Am Coll Cardiol; 2010 Sep; 56(12):956-65. PubMed ID: 20828648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study.
    Nelson MR; Reid CM; Ames DA; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Krum H; Storey E; Tonkin A; Wolfe R; Woods R; McNeil JJ
    Med J Aust; 2008 Jul; 189(2):105-9. PubMed ID: 18637782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
    Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
    J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term impact of aspirin cessation in older adults: a target trial emulation.
    Zhou Z; Webb KL; Nelson MR; Woods RL; Ernst ME; Murray AM; Chan AT; Tonkin A; Reid CM; Orchard SG; Kirpach B; Shah RC; Stocks N; Broder JC; Wolfe R
    BMC Med; 2024 Jul; 22(1):306. PubMed ID: 39075484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aspirin in reducing events in the elderly trial: Statistical analysis plan.
    Wolfe R; Murray AM; Woods RL; Kirpach B; Gilbertson D; Shah RC; Nelson MR; Reid CM; Ernst ME; Lockery J; Donnan GA; Williamson J; McNeil JJ
    Int J Stroke; 2018 Apr; 13(3):335-338. PubMed ID: 29111960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.